Buti M - Search Results

1

Manns MP, Buti M, Gane E, Pawlotsky JM, Razavi H, Terrault N, Younossi Z. Manns MP, et al. Among authors: buti m. Nat Rev Dis Primers. 2017 Mar 2;3:17006. doi: 10.1038/nrdp.2017.6. Nat Rev Dis Primers. 2017. PMID: 28252637 Review.

2

Influence of human immunodeficiency virus infection on cell-mediated immunity in chronic D hepatitis.

Buti M, Esteban R, Español MT, Malagelada A, Jardi R, Rodriguez-Frias F, Roget M, Guardia J. Buti M, et al. J Infect Dis. 1991 Jun;163(6):1351-3. doi: 10.1093/infdis/163.6.1351. J Infect Dis. 1991. PMID: 1674749

3

Hepatitis C virus antibodies among risk groups in Spain.

Esteban JI, Esteban R, Viladomiu L, López-Talavera JC, González A, Hernández JM, Roget M, Vargas V, Genescà J, Buti M, et al. Esteban JI, et al. Among authors: buti m. Lancet. 1989 Aug 5;2(8658):294-7. doi: 10.1016/s0140-6736(89)90485-6. Lancet. 1989. PMID: 2569102

4

Chronic delta hepatitis: is the prognosis worse when associated with hepatitis C virus and human immunodeficiency virus infections?

Buti M, Jardi R, Allende H, Cotrina M, Rodriguez F, Viladomiu L, Esteban R, Guardia J. Buti M, et al. J Med Virol. 1996 May;49(1):66-9. doi: 10.1002/(SICI)1096-9071(199605)49:1<66::AID-JMV11>3.0.CO;2-0. J Med Virol. 1996. PMID: 8732862

5

Quantification of serum hepatitis C virus RNA with daily or standard interferon doses plus ribavirin in nonresponder patients with chronic hepatitis C.

Buti M, Olive G, Stalgis C, Esteban R, Guardi J. Buti M, et al. Dig Dis Sci. 2000 Apr;45(4):685-9. doi: 10.1023/a:1005479207106. Dig Dis Sci. 2000. PMID: 10759235

6

[Prevalence and incidence of hepatitis A in patients with hepatitis B and C].

Olivé G, Buti M, Ignacio Esteban J, Cotrina M, Esteban R, Guardia J. Olivé G, et al. Among authors: buti m. Med Clin (Barc). 2000 Sep 9;115(7):254-5. doi: 10.1016/s0025-7753(00)71525-9. Med Clin (Barc). 2000. PMID: 11013148 Spanish.

7

[Treatment of viral hepatitis].

Olive G, Buti M, Esteban R. Olive G, et al. Among authors: buti m. Rev Clin Esp. 2001 Mar;201(3):148-52. doi: 10.1016/s0014-2565(01)70772-2. Rev Clin Esp. 2001. PMID: 11387827 Review. Spanish. No abstract available.

8

High-Dose interferon-alpha2b plus ribavirin for retreatment of interferon-nonresponsive patients infected with genotype 1 hepatitis C virus.

Buti M, Morral S, Sanchez F, Martell M, Stalgis C, Esteban R. Buti M, et al. Dig Dis Sci. 2001 Nov;46(11):2396-400. doi: 10.1023/a:1012355332052. Dig Dis Sci. 2001. PMID: 11713942

9

Viral kinetics in genotype 1 chronic hepatitis C patients during therapy with 2 different doses of peginterferon alfa-2b plus ribavirin.

Buti M, Sanchez-Avila F, Lurie Y, Stalgis C, Valdés A, Martell M, Esteban R. Buti M, et al. Hepatology. 2002 Apr;35(4):930-6. doi: 10.1053/jhep.2002.32150. Hepatology. 2002. PMID: 11915041 Clinical Trial.

10

The predictive value of core antigen testing for the management of hepatitis C patients receiving pegylated interferon/ribavirin treatment.

Pradat P, Maynard M, Buti M, Berthillon P, Picchio G, Tillmann HL, Wiegand J, Voirin N, Manns MP, Esteban JI, Martinot M, Marcellin P, Trepo C. Pradat P, et al. Among authors: buti m. J Med Virol. 2004 Jul;73(3):392-6. doi: 10.1002/jmv.20104. J Med Virol. 2004. PMID: 15170634

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

637 results

Search Page